Dr. Jun Ishihara is a Lecturer (equivalent to Assistant Professor in the USA) in the Department of Bioengineering at Imperial College London. The Ishihara laboratory works in the field of protein engineering, with research foci in cancer immunotherapy, autoimmunity, and regenerative medicine.
Dr. Ishihara received his PhD in stem cell biology from the University of Tokyo. He then conducted postdoctoral training in the laboratory of Jeffrey Hubbell first at the Ecole Polytechnique Fédérale de Lausanne (EPFL) in Switzerland from 2014 to 2016 and then at the University of Chicago from 2016 to 2020 when the laboratory relocated to the Pritzker School of Molecular Engineering.
Dr. Ishihara has developed novel technologies in the field of immuno-engineering in order to improve current therapies and discover new drugs. He has developed novel approaches to cancer immunotherapy that achieve localised immune activation by targeting the tumour microenvironment. These methods make cancer immunotherapy safe and effective. Dr. Ishihara has also engineered treatments for autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. In the field of regenerative medicine, he has developed novel approaches to efficiently deliver growth factors to the wound site to promote wound healing.
Dr. Ishihara has co-authored 19 scientific papers and 16 patents, with publications in Nature Biomedical Engineering, Science Translational Medicine, Science Advances, Blood and Nature Communications. He is also a co-founder of Arrow Immune Inc., focusing on clinical translation of cancer immunotherapy techniques, HeioThera Inc., focusing on clinical translation of anti-inflammatory the therapeutics, and ScienceLounge LLC., which runs a science bar in Tokyo for scientific outreach activities.
"Prolonged residence of an albumin–IL-4 fusion protein in secondary lymphoid organs ameliorates experimental autoimmune encephalomyelitis"
Ishihara A, Ishihara J#, Watkins EA, Tremain AC, Nguyen M, Solanki A, Katsumata K, Mansurov A, Budina E, Alpar AT, Hosseinchi P, Maillat L, Reda JW, Kageyama T, Swartz MA, Yuba E, Hubbell JA#
Nature Biomedical Engineering 5, pages387–398 (2021). DOI:10.1038/s41551-020-00627-3
"Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours"
Mansurov A*, Ishihara J#*, Hosseinchi P, Potin L, Marchell TM, Ishihara A, Williford J-M, Alpar AT, Raczy MM, Gray LT, Swartz MA, Hubbell JA
Nature Biomedical Engineering 4, 531-543 (2020).
"Conferring extracellular matrix affinity enhances local therapeutic efficacy of anti-TNF-α antibody in a murine model of rheumatoid arthritis"
Katsumata K, Ishihara J, Fukunaga K, Ishihara A, Yuba E, Budina E, Hubbell JA
Arthritis Research and Therapy 21, 1-10 (2019).
"Recruitment of CD103+ dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy"
Williford J-M*, Ishihara J*, Ishihara A, Mansurov A, Hosseinchi P, Marchell TM, Potin L, Swartz MA, Hubbell JA
Science Advances 5, 1-15 (2019). DOI:10.1126/sciadv.aay1357
"Targeting inflammatory sites through collagen affinity enhances the therapeutic efficacy of anti-inflammatory antibodies"
Katsumata K, Ishihara J, Mansurov A, Ishihara A, Raczy MM, Yuba E, Hubbell JA
Science Advances 5, 1-9 (2019). DOI:10.1126/sciadv.aay1971
"Engineered collagen-binding serum albumin as a drug conjugate carrier for cancer therapy"
Sasaki K*, Ishihara J*, Ishihara A, Miura R, Mansurov A, Fukunaga K, Hubbell JA
Science Advances 5, 1-12 (2019). DOI:10.1126/sciadv.aaw6081
"The heparin binding domain of von Willebrand factor binds to growth factors and promotes angiogenesis in wound healing"
Ishihara J, Ishihara A, Starke RD, Peghaire CR, Smith KE, McKinnon TAJ, Tabata Y, Sasaki K, White MJV, Fukunaga K, Laffan MA, Lutolf MP, Randi AM, Hubbell JA
Blood 133, 2559-2569 (2019). DOI:10.1182/blood.2019000510
"Targeted antibody and cytokine cancer immunotherapies through collagen affinity"
Ishihara J*, Ishihara A*, Sasaki K, Lee SS-Y, Williford J-M, Yasui M, Abe H, Potin L, Hosseinchi P, Fukunaga K, Raczy MM, Gray LT, Mansurov A, Katsumata K, Fukayama M, Kron SJ, Swartz MA, Hubbell JA
Science Translational Medicine 11, 1-13 (2019). DOI:10.1126/scitranslmed.aau3259
"Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity"
Ishihara J*, Ishihara A*, Potin L, Hosseinchi P, Fukunaga K, Damo M, Gajewski TF, Swartz MA, Hubbell JA
Molecular Cancer Therapeutics 17, 2399-2411 (2018). DOI:10.1158/1535-7163.MCT-18-0091
"Laminin heparin-binding peptides bind to several growth factors and enhance diabetic wound healing"
Ishihara J, Ishihara A, Fukunaga K, Sasaki K, White MJV, Briquez PS, Hubbell JA
Nature Communications 9, 1-14 (2018).
"Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events"
Ishihara J, Fukunaga K, Ishihara A, Larsson HM, Potin L, Hosseinchi P, Galliverti G, Swartz MA, Hubbell JA
Science Translational Medicine 9, 1-16 (2017).
"Stripe‐Patterned Thermo‐responsive Cell Culture Dish for Cell Separation without Cell Labeling"
Kumashiro Y, Ishihara J, Umemoto T, Itoga K, Kobayashi J, Shimizu T, Yamato M, Okano T
Small 11, 681-687 (2015). DOI:10.1002/smll.201400787
"A role for c-Kit in the maintenance of undifferentiated human mesenchymal stromal cells"
Suphanantachat S, Iwata T, Ishihara J, Yamato M, Okano T, Izumi Y
Biomaterials 35, 3618-3626 (2014). DOI:10.1016/j.biomaterials.2014.01.031
"Nov/CCN3 regulates long-term repopulating activity of murine hematopoietic stem cells via integrin αvβ3"
Ishihara J, Umemoto T, Yamato M, Shiratsuchi Y, Takaki S, Petrich BG, Nakauchi H, Eto K, Kitamura T, Okano T
International Journal of Hematology 99, 393-406 (2014).
"Requirement of Integrin β3 for Iron Transportation during Enamel Formation"
Yoshida T, Kumashiro Y, Iwata T, Ishihara J, Umemoto T, Shiratsuchi Y, Kawashima N, Sugiyama T, Yamato M, Okano T
Journal of Dental Research 91, 1154-1159 (2012). DOI:10.1177/0022034512462722
"Integrin-αvβ3 regulates thrombopoietin-mediated maintenance of hematopoietic stem cells"
Umemoto T, Yamato M, Ishihara J, Shiratsuchi Y, Utsumi M, Morita Y, Tsukui H, Terasawa M, Shibata T, Nishida K, Kobayashi Y, Petrich BG, Nakauchi H, Eto K, Okano T
Blood 119, 1, 83-94 (2012). DOI:10.1182/blood-2011-02-335430